menu
    • menu
    [{"orgOrder":0,"company":"Navitor Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"NV-5138","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Navitor Pharmaceuticals","amount2":0.47999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.47999999999999998,"dosageForm":"Oral","sponsorNew":"Navitor Pharmaceuticals \/ Supernus","highestDevelopmentStatusID":"6","companyTruncated":"Navitor Pharmaceuticals \/ Supernus"},{"orgOrder":0,"company":"Navitor Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SPN-820","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Navitor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Navitor Pharmaceuticals \/ Navitor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Navitor Pharmaceuticals \/ Navitor Pharmaceuticals"},{"orgOrder":0,"company":"Navitor Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SPN-820","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Navitor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Navitor Pharmaceuticals \/ Navitor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Navitor Pharmaceuticals \/ Navitor Pharmaceuticals"},{"orgOrder":0,"company":"Navitor Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPN-820","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Navitor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Navitor Pharmaceuticals \/ Navitor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Navitor Pharmaceuticals \/ Navitor Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Navitor Pharmaceuticals

    Menu

    Navitor Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Navitor Pharmaceuticals

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Navitor Pharmaceuticals

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPN-820

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Supernus Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Supernus Announces Topline Results from Phase 2b Study in Adults with TRD

                            Details : SPN-820 is a novel small molecule activator of the mechanistic target of rapamycin complex 1 (mTORC1) currently under development for use in treatment resistant depression.

                            Product Name : SPN-820

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 18, 2025

                            Lead Product(s) : SPN-820

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Supernus Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Navitor Pharmaceuticals

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Navitor Pharmaceuticals

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPN-820

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Supernus Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Supernus Links Depression Drug to Fast Responses in Ph. 2 Trial

                            Details : SPN-820 is a novel small molecule activator of the mechanistic target of rapamycin complex 1 (mTORC1) currently under phase 2 development for use in major depressive disorder.

                            Product Name : SPN-820

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 18, 2024

                            Lead Product(s) : SPN-820

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Supernus Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Navitor Pharmaceuticals

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Navitor Pharmaceuticals

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPN-820

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Supernus Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Dr. Vince Clinical Announces First Dosing in Phase II Study for Patients With Depression

                            Details : SPN-820 is a novel small molecule activator of the mechanistic target of rapamycin complex 1 (mTORC1) currently under phase 2 development for use in major depressive disorder.

                            Product Name : SPN-820

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 13, 2024

                            Lead Product(s) : SPN-820

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Supernus Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Navitor Pharmaceuticals

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Navitor Pharmaceuticals

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NV-5138

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Supernus Pharmaceuticals

                            Deal Size : $475.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138

                            Details : Under the terms of the agreement, Supernus and Navitor will jointly conduct a Phase II clinical program for NV-5138 in treatment-resistant depression (TRD).

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : $25.0 million

                            April 21, 2020

                            Lead Product(s) : NV-5138

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Supernus Pharmaceuticals

                            Deal Size : $475.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth